Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...